Posted by MD Biosciences on Mon, Jan 11, 2010 @ 11:54 AM
Sodium and calcium cation channel blockers.
There are several types of drugs that have been developed to
decrease the firing rate of nociceptive neurons by blocking cation channels.
Among the most commonly known are lidocaine and bupivacaine, typically used as
local anesthetics, which form an intracellular block of the voltage gated
sodium channels (VGSCs) that are necessary for action potential generation.
Without action potential firing, nociceptors are unable to propagate their
message, and pain is thereby blocked. The main disadvantage of this class of
drugs is that without selectivity for nociceptive sensory neurons, tactile
input is also lost, leading to the numbness that accompanies local anesthetic
administration.
Sodium
channel blockers are most commonly used to treat neuropathic and other types of
chronic pain; as such, models of neuropathic pain, particularly peripheral neuropathy
models, are an excellent option for testing novel compounds of this drug class.
Their analgesic efficacy may be more widespread, however, as they have shown to
be useful against inflammatory pain and in some post-operative pain models.
Notably, they are also among the few drug types shown to be effective in models
of visceral pain.
Voltage
gated calcium channels (VGCC) are another pharmacological target for pain
relief. Gabapentin and pregabalin fall under the classification of
gabapentinoids, which, while structurally similar to the endogenous
neurotransmitter GABA, do not function as such. Instead, they bind to the α2-δ
subunit of VGCC to reduce calcium influx into nerve terminals and thereby
decrease neurotransmitter release. The α2-δ
subunit of VGCC is highly expressed in the dorsal horn of the spinal cord, and
decreasing the release of glutamate and substance P from nociceptive primary
afferent neurons here is likely the main mechanism of action for drugs of this
type. However, disinhibition of endogenous descending inhibitory pathways at
supraspinal sites may also contribute to their analgesic effects (1). Gabapentinoids are tested
primarily in models of neuropathic pain, including both nerve injury and
neuropathy models, which reflects their clinical utility.
TRPV1 ligands
The
development of more selective cation channel blockers as a solution to avoiding
the side effects that accompany a general neuronal blockade has been the
subject of much investigation recently. Transient receptor potential (TRP)
channels are attractive targets, as they are predominantly expressed in
nociceptive DRG neurons. Activation of TRP channels, therefore, has little or
no effect on normal mechanical sensation, and drugs that target these channels
could potentially avoid centrally-mediated side effects as well.
TRPV1 channels, in particular, are
widely studied as a potential therapeutic target. TRPV1 is a non-selective
cation channel is activated by capsaicin, the active ingredient in chili peppers,
as well as heat. The function of TRPV1 is also modulated by a variety of
sensitizing agents released after injury, including protons. Inflammation
resulting from injury can reduce tissue pH, thereby activating TRPV1, causing
an increase in sodium and calcium influx into the cell, and thereby
contributing to the sensitization of nociceptors under these conditions (2). TRPV1 can be targeted
through either antagonists to block activation directly or with agonists, which
work by causing desensitization of the receptor following robust activation.
Given
the effects of inflammation on TRPV1 function, it is not surprising that
ligands for this receptor have shown efficacy in a variety of inflammatory pain
models, including post-surgical and arthritic pain as well as standard
inflammatory pain models (2). Similar to other cation
channel blockers, they are also effective in models of neuropathic pain,
particularly peripheral neuropathy models, and in some models of visceral pain.
Efficacy Models of Pain
Speak with a scientist about evaluating a compound in a model of pain
Whitepapers: Peripheral Nerve Injury models and Post-operative pain models
References:
-
Tanabe, M., et
al., Pain relief by gabapentin and pregabalin via supraspinal mechanisms
after peripheral nerve injury. J Neurosci
Res, 2008. 86(15): p. 3258-64.
Patapoutian,
A., S. Tate, and C.J. Woolf, Transient receptor potential channels:
targeting pain at the source. Nat Rev Drug Discov, 2009. 8(1): p. 55-68
Posted by MD Biosciences on Tue, Nov 17, 2009 @ 02:00 PM
The body's cannabinoid system consists of two cannabinoid receptors, CB1 and CB2, their endogenous ligands, which include 2-arachidonoyl glycerol (2-AG) and anandamide (AEA), and the enzymes that regulate the synthesis and degradation of these ligands. While the endogenous cannabinoid system serves naturally to modulate pain transmission, it can be exploited to provide more robust relief, either through administration of agonists at CB1 or CB2 receptors or through inhibition of degrading enzymes to increase endogenous cannabinoid levels.
CB1 receptors are expressed in neurons throughout the central and peripheral nervous system, including in the DRG, where noiciceptor cell bodies reside, the dorsal horn of the spinal cord, and the PAG, all of which are important sites for modulation of pain transmission. CB2 receptors, on the other hand, are not found in the CNS under normal conditions (although they may be upregulated in nociceptive neurons after injury) and are instead expressed in a variety immune cells and microglia. Although activation of either receptor can promote pain relief, CB1 receptors are responsible for the centrally-mediated psychomimetic side effects that sometimes accompany administration of cannabinoid receptor agonists such as tetrahydrocannabinol (THC).
Both CB1 and CB2 are GPCRs that signal predominantly through Gi/o to decrease VGCC conductance and activate GIRKs to hyperpolarize cells. Therefore, ligand binding to cannabinoid receptors results in decreased release of excitatory neurotransmitters from nociceptive neurons and post-synaptic cells exhibiting decreased excitability for signals they do receive. Activation of cannabinoid receptors on immune cells can similarly inhibit their function and thereby indirectly modulate pain processing. Since CB2 receptors are found primarily on immune cells and microglia, this indirect, anti-inflammatory effect is the primary mechanism by which CB2-selective agonists modulate pain responses.
Cannabinoid agonists have shown efficacy in
acute models such as
tail flick and
capsaicin injection, as well as
carrageenan and CFA inflammatory pain models. Translation from animal models to the human condition has been documented for a variety of neuropathic conditions as well as for post-operative pain relief; therefore, both
neuropathic and post-operative pain models would be appropriate for testing novel compounds designed to target the cannabinoid system as well.
Posted by MD Biosciences on Wed, Oct 14, 2009 @ 02:14 PM
α2-adrenergic receptors (α2ARs) are found in many areas in throughout the nervous system, but the α2ARs on pre- and post-synaptic neurons in the dorsal horn of the spinal cord are the main target for both endogenous and exogenous analgesia. One of the major descending inhibitory pain pathways involves the projection of noradrenergic neurons in the locus ceruleus back down to the spinal cord to activate α2ARs at this site. These receptors can also be targeted pharmacologically through administration of selective agonists or through the inhibition of noradrenaline (also known as norepinephrine) reuptake by drugs such as tricyclic antidepressants.
α2ARs are divided into three subtypes, the α2A-, α2B- and α2C-ARs. All three are Gi/o coupled GPCRs. α2AARs are expressed mostly on the central, pre-synaptic terminals of nociceptors and inhibit VGCC on these terminals to reduce the release of excitatory neurotransmitters such as glutamate and substance P. At the same time, α2CARs, expressed primarily on the second order neurons in the dorsal horn, reduce excitability of these neurons by increasing conductance through GIRK channels [1].
Tricyclic antidepressants (TCAs) are used clinically for the treatment of various neuropathic pain conditions, including nerve injury and diabetic neuropathy. Importantly, their analgesic efficacy is independent of the co-existence of depression in patients. Most TCAs have some action on both serotonin and norepinephrine reuptake, but their analgesic actions are largely mediated by increasing spinal noradrenergic tone coming from descending pathways, which then increases activation of α2ARs to produce pain relief as described above.
In accordance with their clinical usage, animal models of neuropathic pain are widely used to test novel TCAs. In fact, TCAs show little efficacy in animal models of acute or inflammatory pain. Although neuropathic and other forms of chronic pain are common indications for the clinical use of α2AR agonists as well, they show robust antinociception in a much wider variety of animal models, including acute and inflammatory ones. Also, they are used both clinically for and in animal models of postoperative pain [1].
Reference
1. Pan, H.L., et al., Modulation of pain transmission by G-protein-coupled receptors. Pharmacol Ther, 2008. 117(1): p. 141-61.